Why is Sun Pharma Advanced Research Company Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
Low Debt Company with Strong Long Term Fundamental Strength
3
Flat results in Sep 26
- NET SALES(Q) At Rs 30.03 cr has Fallen at -93.7% (vs previous 4Q average)
- PBT LESS OI(Q) At Rs -47.93 cr has Fallen at -112.2% (vs previous 4Q average)
- PAT(Q) At Rs -24.39 cr has Fallen at -106.1% (vs previous 4Q average)
4
Stock is technically in a Mildly Bullish range
- Multiple factors for the stock are Bullish like Bollinger Band, KST and OBV
5
With ROE of 114.3, it has a Expensive valuation with a 4.3 Price to Book Value
- Over the past year, while the stock has generated a return of 37.54%, its profits have risen by 717.3% ; the PEG ratio of the company is 0
6
Despite the size of the company, domestic mutual funds hold only 0.28% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
7
Market Beating Performance
- The stock has generated a return of 37.54% in the last 1 year, much higher than market (BSE500) returns of 0.37%
How much should you hold?
- Overall Portfolio exposure to SPARC should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is SPARC for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
SPARC
37.54%
0.63
59.81%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
466.97%
EBIT Growth (5y)
142.91%
EBIT to Interest (avg)
-33.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.87
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.85%
ROCE (avg)
36.32%
ROE (avg)
38.10%
Valuation Key Factors 
Factor
Value
P/E Ratio
4
Industry P/E
40
Price to Book Value
4.29
EV to EBIT
3.01
EV to EBITDA
2.99
EV to Capital Employed
33.41
EV to Sales
2.53
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
1111.20%
ROE (Latest)
114.29%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Technical Movement
14What is working for the Company
NET SALES(Latest six months)
At Rs 69.95 cr has Grown at 299.71%
PAT(9M)
Higher at Rs 1,716.17 Cr
-11What is not working for the Company
NET SALES(Q)
At Rs 30.03 cr has Fallen at -93.7% (vs previous 4Q average
PBT LESS OI(Q)
At Rs -47.93 cr has Fallen at -112.2% (vs previous 4Q average
PAT(Q)
At Rs -24.39 cr has Fallen at -106.1% (vs previous 4Q average
OPERATING PROFIT TO INTEREST (Q)
Lowest at -380.08 times
Loading Valuation Snapshot...
Here's what is not working for SPARC
Net Sales - Quarterly
At Rs 30.03 cr has Fallen at -93.7% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 477.36 CrMOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -47.93 cr has Fallen at -112.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 392.76 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs -24.39 cr has Fallen at -106.1% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 399.16 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Operating Profit to Interest - Quarterly
Lowest at -380.08 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest